Krystal Biotech, Inc. $KRYS is Odyssean LLC’s 10th Largest Position

Odyssean LLC grew its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) by 94.0% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,349 shares of the company’s stock after acquiring an additional 4,530 shares during the quarter. Krystal Biotech accounts for 0.6% of Odyssean LLC’s portfolio, making the stock its 10th biggest holding. Odyssean LLC’s holdings in Krystal Biotech were worth $3,475,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently modified their holdings of KRYS. Silvant Capital Management LLC purchased a new position in shares of Krystal Biotech in the 2nd quarter worth about $30,000. Western Wealth Management LLC bought a new position in Krystal Biotech in the 1st quarter worth about $34,000. Greenline Wealth Management LLC purchased a new stake in Krystal Biotech during the 4th quarter valued at about $34,000. UMB Bank n.a. grew its position in Krystal Biotech by 34.6% during the 4th quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the last quarter. Finally, Global Retirement Partners LLC increased its stake in Krystal Biotech by 788.9% during the 4th quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares in the last quarter. 86.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on KRYS. Chardan Capital raised shares of Krystal Biotech to a “strong-buy” rating in a report on Monday, August 3rd. Citigroup raised their price target on shares of Krystal Biotech from $378.00 to $386.00 and gave the company a “buy” rating in a research report on Tuesday, August 4th. Bank of America boosted their price objective on shares of Krystal Biotech from $364.00 to $396.00 and gave the stock a “buy” rating in a report on Tuesday, July 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $474.00 price objective on shares of Krystal Biotech in a research report on Monday, July 13th. Finally, TD Cowen increased their target price on Krystal Biotech from $306.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, June 18th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $365.40.

Krystal Biotech Stock Down 3.6%

Shares of NASDAQ KRYS opened at $358.24 on Friday. The firm’s 50-day moving average price is $349.81 and its 200-day moving average price is $307.38. Krystal Biotech, Inc. has a 52-week low of $136.73 and a 52-week high of $382.54. The company has a market cap of $10.60 billion, a PE ratio of 44.89 and a beta of 0.54.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, August 3rd. The company reported $1.79 earnings per share for the quarter, beating the consensus estimate of $1.70 by $0.09. The firm had revenue of $119.22 million during the quarter, compared to analysts’ expectations of $120.93 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. As a group, equities research analysts anticipate that Krystal Biotech, Inc. will post 7.48 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, Director Dino Rossi sold 25,000 shares of the business’s stock in a transaction on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at approximately $16,456,000. The trade was a 33.33% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Friday, September 4th. The shares were sold at an average price of $359.32, for a total value of $8,983,000.00. Following the transaction, the insider directly owned 1,302,145 shares in the company, valued at $467,886,741.40. The trade was a 1.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 51,000 shares of company stock valued at $17,558,270. Company insiders own 13.10% of the company’s stock.

Krystal Biotech Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.